PD-L1 |
Programmed cell death ligand-1 |
PD-1 |
Programmed cell death protein-1 |
HNSCC |
Head and neck squamous cell carcinoma |
siRNA |
Small interfering ribonucleic acid |
EMT |
Epithelial–mesenchymal transition |
FDA |
Food and Drug Administration |
PD-L2 |
Programmed cell death ligand 2 |
IFN |
Interferon |
APC |
Antigen-presenting cell |
PCI |
Pittsburgh Cancer Institute |
NT |
Nontargeting |
KD |
Knockdown |
CV |
Control vector |
OE |
Overexpression |
RAC2 |
Gene encoding for the small Rho-GTPase Rac2 |
ARGHDIA |
Gene encoding for Rho-GDP-dissociation inhibitor 1 |
PAK4 |
Gene encoding for serine/threonine-protein kinase PAK 4 |
ITGA4 |
Gene encoding for integrin alpha 4 |
MMP9 |
Gene encoding for matrix-metalloproteinase 9 |
RHO |
Gene encoding for the small Rho-GTPase Rho |
qPCR |
Quantitative polymerase chain reaction |
DMEM |
Dulbecco’s modified Eagle’s medium |
FCS |
Fetal calf serum |
EDTA |
Ethylenediaminetetraacetic acid |
DAB |
3,3′-Diaminobenzidine |
PBS |
Phosphate buffered saline |
PVDF |
Polyvinylidene fluoride |
SDS-PAGE |
Sodium dodecyl sulfate polyacrylamide gel electrophoresis |
γ |
Gamma |
SD |
Standard deviation |